「Pulsating, duration of 4–72 hOurs,Unilateral,Nausea,Disabling(拍動、4-72時間の持続、片側性、吐き気、障害)」の略であるPOUNDingという語は片頭痛の診断に役立っている。上の5つの基準のうち4つが合致した場合、その片頭痛の診断における陽性尤度比は24となる。
^Ogilvie AD, Russell MB, Dhall P, et al. (January 1998). “Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura”. Cephalalgia18 (1): 23–6. doi:10.1046/j.1468-2982.1998.1801023.x. PMID9601620.
^Gervil M, Ulrich V, Kaprio J, Olesen J, Russell MB (September 1999). “The relative role of genetic and environmental factors in migraine without aura”. Neurology53 (5): 995–9. doi:10.1212/WNL.53.5.995. PMID10496258.
^Headache Classification Subcommittee of the International Headache Society (2004). “The International Classification of Headache Disorders: 2nd edition”. Cephalalgia24 Suppl 1: 9–160. doi:10.1111/j.1468-2982.2004.00653.x. PMID14979299.
^Lipton RB, Stewart WF, Celentano DD, Reed ML (June 1992). “Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis”. Archives of Internal Medicine152 (6): 1273–8. doi:10.1001/archinte.152.6.1273. PMID1599358.
^Schreiber CP, Hutchinson S, Webster CJ, Ames M, Richardson MS, Powers C (September 2004). “Prevalence of migraine in patients with a history of self-reported or physician-diagnosed 'sinus' headache”. Archives of Internal Medicine164 (16): 1769–72. doi:10.1001/archinte.164.16.1769. PMID15364670.
^Detsky ME, McDonald DR, Baerlocher MO, Tomlinson GA, McCrory DC, Booth CM (September 2006). “Does this patient with headache have a migraine or need neuroimaging?”. JAMA296 (10): 1274–83. doi:10.1001/jama.296.10.1274. PMID16968852.
^ abSimon RP, Aminoff MJ, Greenberg DA (2009). Clinical neurology (7 ed.). New York, N.Y: Lange Medical Books/McGraw-Hill. pp. 85–88. ISBN9780071664332。
^Wan D, Wang C, Zhang X, Tang W, Chen M, Dong Z, Yu S (1 January 2016). "Association between angiotensin-converting enzyme insertion/deletion polymorphism and migraine: a meta-analysis". The International Journal of Neuroscience. 126 (5): 393–9. doi:10.3109/00207454.2015.1025395. PMID26000817. S2CID34902092。
^Martin PR (June 2010). "Behavioral management of migraine headache triggers: learning to cope with triggers". Current Pain and Headache Reports. 14 (3): 221–7. doi:10.1007/s11916-010-0112-z. PMID20425190. S2CID5511782。
^Pavlovic JM, Buse DC, Sollars CM, Haut S, Lipton RB (2014). "Trigger factors and premonitory features of migraine attacks: summary of studies". Headache. 54 (10): 1670–9. doi:10.1111/head.12468. PMID25399858. S2CID25016889。
^Sun-Edelstein C, Mauskop A (June 2009). “Foods and supplements in the management of migraine headaches”. The Clinical Journal of Pain25 (5): 446–52. doi:10.1097/AJP.0b013e31819a6f65. PMID19454881.
^Yang WH, Drouin MA, Herbert M, Mao Y, Karsh J (June 1997). “The monosodium glutamate symptom complex: assessment in a double-blind, placebo-controlled, randomized study”. The Journal of Allergy and Clinical Immunology99 (6 Pt 1): 757–62. doi:10.1016/S0091-6749(97)80008-5. PMID9215242.
^Tarasoff L, Kelly MF (December 1993). “Monosodium L-glutamate: a double-blind study and review”. Food and Chemical Toxicology31 (12): 1019–35. doi:10.1016/0278-6915(93)90012-N. PMID8282275.
^ abcAlexander Mauskop; Fox, Barry (2001). What Your Doctor May Not Tell You About(TM): Migraines : The Breakthrough Program That Can Help End Your Pain. New York: Warner Books. ISBN0-446-67826-0[要ページ番号]
^Lauritzen M (February 1994). “Pathophysiology of the migraine aura. The spreading depression theory”. Brain117 (1): 199–210. doi:10.1093/brain/117.1.199. PMID7908596.
^ abcdeKaniecki R, Lucas S. (2004). “Treatment of primary headache: preventive treatment of migraine”. Standards of care for headache diagnosis and treatment. Chicago: National Headache Foundation. pp. 40–52
^ abBrandes JL, Kudrow D, Stark SR, et al. (April 2007). “Sumatriptan-naproxen for acute treatment of migraine: a randomized trial”. JAMA297 (13): 1443–54. doi:10.1001/jama.297.13.1443. PMID17405970.
^Goldstein J, Hoffman HD, Armellino JJ, et al. (September 1999). “Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine”. Cephalalgia19 (7): 684–91. doi:10.1046/j.1468-2982.1999.019007684.x. PMID10524663.
^Orr SL, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35(3):271-284.
^Diener H, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, Gallai V, Göbel H, Hartung E, Jimenez M, Lange R, Manzoni G, Mueller-Schwefe G, Nappi G, Pinessi L, Prat J, Puca F, Titus F, Voelker M (2004). “Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks”. Cephalalgia24 (11): 475. doi:10.1111/j.1468-2982.2004.00783.x. PMID15482357.
^Silberstein SD, Mannix LK, Goldstein J, et al. (2008). “Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine”. Neurology71 (2): 114–21. doi:10.1212/01.wnl.0000316800.22949.20. PMID18606965.
^Fritsche G, Diener HC (November 2002). “Medication overuse headaches -- what is new?”. Expert Opinion on Drug Safety1 (4): 331–8. doi:10.1517/14740338.1.4.331. PMID12904133.
^Millan MJ.(2005)"Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies." 2005 Sep-Oct;60(5):441-60. PMID16433010
^RK Cady, CP Schreiber, ME Beach, CC Hart (2005). “Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase”. Medical Science Monitor11 (9): PI65–9. PMID16127373. See also summary poster
^Russo, Ethan (1998). Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain 76:3-8.
^ abEtminan M, Takkouche B, Isorna FC, et al. Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ. 2005;330:63. PMID15596418
^ abKurth, T; Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE (2006). “Migraine and risk of cardiovascular disease in women”. JAMA296 (3): 283–91. doi:10.1001/jama.296.3.283. PMID16849661.
^Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR. Migraine and the risk of stroke, TIA, or death in the UK (CME). Headache. 2007;47(10):1374–84. PMID18052947
^Waters WE, Campbell MJ, Elwood PC. Migraine, headache, and survival in women. BMJ (Clin Res Ed). 1983;287:1442–1443. PMID6416449
^Ottman R, Lipton RB (1994). “Comorbidity of migraine and epilepsy”. Neurology44 (11): 2105–10. PMID7969967.
^Mortimer MJ, Kay J, Jaron A (1992). “Epidemiology of headache and childhood migraine in an urban general practice using Ad Hoc, Vahlquist and IHS criteria”. Dev Med Child Neurol34 (12): 1095–101. PMID1451940.
^Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M (1989). “An epidemiologic study of headache among adolescents and young adults”. JAMA261 (15): e1197. doi:10.1001/jama.261.15.2211. PMID2926969.
^Ziegler DK, Hassanein RS, Couch JR (1977). “Characteristics of life headache histories in a nonclinic population”. Neurology27 (3): 265–9. PMID557763.
^ abAnttila P, Metsähonkala L, Sillanpää M (2006). “Long-term trends in the incidence of headache in Finnish schoolchildren”. Pediatrics117 (6): e1197–201. doi:10.1542/peds.2005-2274. PMID16740819.
^ abcLipton RB, Stewart WF (1993). “Migraine in the United States: a review of epidemiology and health care use”. Neurology43 (6 Suppl 3): S6–10. PMID8502385.
^ abRasmussen BK, Olesen J (1992). “Migraine with aura and migraine without aura: an epidemiological study”. Cephalalgia12 (4): 221–8; discussion 186. doi:10.1046/j.1468-2982.1992.1204221.x. PMID1525797.
^Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003). “The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity”. Cephalalgia23 (7): 519–27. doi:10.1046/j.1468-2982.2003.00568.x. PMID12950377.
^Stewart WF, Linet MS, Celentano DD, Van Natta M, Ziegler D (1991). “Age- and sex-specific incidence rates of migraine with and without visual aura”. Am. J. Epidemiol.134 (10): 1111–20. PMID1746521.
^ abcArulmani, U., "Calcitonin Gene-Related Peptide and Migraine: Implications for Therapy" (2004). Doctoral thesis, Erasmus University. Web-link.
^Brothwell, Don R. (1963). Digging up Bones; the Excavation, Treatment and Study of Human Skeletal Remains. London: British Museum (Natural History). pp. 126. OCLC14615536
Federation of American Societies for Experimental Biology . Analysis of adverse reactions to monosodium glutamate (MSG). Bethesda, MD: Life Sciences Research Office, FASEB.
Pashley, H. (2009). About Migraine Triggers.
Radnitz, C. L. (1990). Food-triggered migraine: a critical review. Annals of Behavioral Medicine, 12, 51–65.
Ravishankar, K (2006). 'Hair wash' or 'Head bath' triggering migraine - observations in 94 Indian patients". Cephalagia 26 (11): 1330–1334. ISSN 0333-1024.
治療
Pearce, J.M.S. (1994). Headache.Neurological Management series. Journal of Neurology Neurosurgery and Psychiatry.57, 134–144.
Mayo Clinic Staff. (2005). Migraine Headache. Retrieved August 14, 2005
Cohen JA, Beall D, Beck A, et al.Sumatriptan treatment for migraine in a health maintenenace organization: economic, humanistic, and clinical outcomes. Clin Ther 1999;21:190–205.
Adelman JU, Sharfman M, Johnson R, et al.Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Manag Care 1996;2:1407–1416.
Cohen JA, Beall DG, Miller DW, Beck A, Pait G, Clements BD. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996;28:171–177.
Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Med Econ 1996;42:36–42.
Solomon GD, Nielsen K, Miller D. The effects of sumatriptan on migraine: health-related quality of life. Med Interface 1995;June:134–141.
Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995;35:449–454.
Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD. Improvement in migrainespecific quality of life in a clinical trial of rizatriptan. Cephalalgia 1997;17:867–872.
Caro JJ, Getsios D. Pharmacoeconomic evidence and considerations for triptan treatment of migraine. Expert Opin Pharmacother 2002;3:237–248.
Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999;159: 857–863.
Cady RC, Ryan R, Jhingran P, O’Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack. Arch Intern Med 1998;158: 1013–1018.
Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 1996;36:538–541.
Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health Syst Pharm 1996;53:633–638.
Lofland JH, Kim SS, Batenhorst AS, et al.Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001;76:1093–1101.
Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 2000;20: 1356–1364.
Caro JJ, Getsios D, Raggio G, Caro G, Black L. Treatment of migraine in Canada with naratriptan: a costeffectiveness analysis. Headache 2001;41:456–464.
経済的影響
Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002;42:501–509.
Gerth WC, Carides GW, Dasbach EJ, Visser WH, Santanello NC. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics 2001;19:197–206.
Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813–818.
Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and low labour costs of migraine headaches in the US. Pharmacoeconomics 1992;2:2–11.
臨床像
Blau JN. Classical migraine: symptoms between visual aura and headache onset. Lancet 1992;340:355-6.
Silberstein SD: Migraine symptoms: Results of a survey of self-reported migraineurs. Headache 1995;35:387-96.
Silberstein SD, Saper JR, Freitag F. Migraine: Diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's headache and other head pain. 7th ed. New York: Oxford University Press, 2001:121–237.